CN108349951B - 双哒嗪化合物 - Google Patents

双哒嗪化合物 Download PDF

Info

Publication number
CN108349951B
CN108349951B CN201680064313.0A CN201680064313A CN108349951B CN 108349951 B CN108349951 B CN 108349951B CN 201680064313 A CN201680064313 A CN 201680064313A CN 108349951 B CN108349951 B CN 108349951B
Authority
CN
China
Prior art keywords
formula
pyridazin
pharmaceutically acceptable
compound
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680064313.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN108349951A (zh
Inventor
M.R.V.芬莱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
AstraZeneca AB
Original Assignee
Cancer Research Technology Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd, AstraZeneca AB filed Critical Cancer Research Technology Ltd
Publication of CN108349951A publication Critical patent/CN108349951A/zh
Application granted granted Critical
Publication of CN108349951B publication Critical patent/CN108349951B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201680064313.0A 2015-11-27 2016-11-25 双哒嗪化合物 Expired - Fee Related CN108349951B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1520959.6 2015-11-27
GBGB1520959.6A GB201520959D0 (en) 2015-11-27 2015-11-27 Bis-pyridazine compounds and their use in treating cancer
PCT/EP2016/078899 WO2017089587A1 (en) 2015-11-27 2016-11-25 Bis-pyridazine compounds and their use in treating cancer

Publications (2)

Publication Number Publication Date
CN108349951A CN108349951A (zh) 2018-07-31
CN108349951B true CN108349951B (zh) 2020-11-13

Family

ID=55177338

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680064313.0A Expired - Fee Related CN108349951B (zh) 2015-11-27 2016-11-25 双哒嗪化合物

Country Status (17)

Country Link
US (2) US10196382B2 (https=)
EP (1) EP3380468B8 (https=)
JP (1) JP2018535226A (https=)
KR (1) KR20180083426A (https=)
CN (1) CN108349951B (https=)
AR (1) AR106849A1 (https=)
AU (1) AU2016360970B2 (https=)
CA (1) CA3005102A1 (https=)
DK (1) DK3380468T3 (https=)
ES (1) ES2806723T3 (https=)
GB (1) GB201520959D0 (https=)
IL (1) IL259358A (https=)
MX (1) MX2018006374A (https=)
RU (1) RU2018122012A (https=)
SG (1) SG11201803814SA (https=)
TW (1) TW201731837A (https=)
WO (1) WO2017089587A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106552296B (zh) 2015-09-29 2020-08-14 上海氪励铵勤科技发展有限公司 纳米粒子、其制备方法与结石取出装置及应用
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
KR20250137464A (ko) 2024-03-11 2025-09-18 이석재 숏블라스트머신의 연마재탱크

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013078123A1 (en) * 2011-11-21 2013-05-30 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
WO2015101958A2 (en) * 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Novel inhibitors of glutaminase

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013078123A1 (en) * 2011-11-21 2013-05-30 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
WO2015101958A2 (en) * 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Novel inhibitors of glutaminase
WO2015101957A2 (en) * 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Novel glutaminase inhibitors

Also Published As

Publication number Publication date
JP2018535226A (ja) 2018-11-29
AU2016360970A1 (en) 2018-07-05
EP3380468B8 (en) 2020-11-04
US10577354B2 (en) 2020-03-03
US10196382B2 (en) 2019-02-05
EP3380468B1 (en) 2020-05-20
AR106849A1 (es) 2018-02-21
AU2016360970B2 (en) 2019-11-07
US20190169172A1 (en) 2019-06-06
EP3380468A1 (en) 2018-10-03
RU2018122012A (ru) 2019-12-30
CA3005102A1 (en) 2017-06-01
MX2018006374A (es) 2019-07-08
KR20180083426A (ko) 2018-07-20
DK3380468T3 (da) 2020-07-27
IL259358A (en) 2018-07-31
WO2017089587A1 (en) 2017-06-01
US20170152244A1 (en) 2017-06-01
SG11201803814SA (en) 2018-06-28
GB201520959D0 (en) 2016-01-13
CN108349951A (zh) 2018-07-31
ES2806723T3 (es) 2021-02-18
TW201731837A (zh) 2017-09-16

Similar Documents

Publication Publication Date Title
US10294221B2 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
JP6821680B2 (ja) 1,3,4−チアジアゾール化合物およびがんの治療におけるその使用
ES2914333T3 (es) Compuestos de 1,3,4-tiadiazol y su uso para tratar cáncer
CN108349951B (zh) 双哒嗪化合物
ES2759940T3 (es) Compuestos de 1,3,4-tiadiazol y su uso para tratar el cáncer
HK1260707B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260707A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20201113

Termination date: 20211125